• Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

The efficacy of 48 weeks treatment with besifovir dipivoxil maleate (BSV) for chronic hepatitis B virus (HBV) infection is comparable to that of tenofovir disoproxil fumarate (TDF), with durable effects for 96 weeks, researchers report in the August issue of Clinical Gastroenterology and Hepatology. BSV has a better safety profile

Read more
  • Why Are Patients Cured of HCV Infection Still at Risk for Liver Cancer?

Why Are Patients Cured of HCV Infection Still at Risk for Liver Cancer?

Chronic infection with the hepatitis C virus (HCV) causes epigenetic changes in liver cells that alter gene expression patterns and continue to affect risk for hepatocellular carcinoma (HCC), regardless of patients’ response to direct-activating antiviral (DAA) agents, researchers report in the June issue of Gastroenterology. These alterations might be targeted

Read more
  • Is it Cost Effective to Transplant HCV-positive Livers Into HCV-negative Patients?

Is it Cost Effective to Transplant HCV-positive Livers Into HCV-negative Patients?

A Markov-based mathematical model estimates that transplanting hepatitis C virus (HCV)-positive livers into HCV-negative patients who have received direct-acting antiviral (DAA) agents would be cost effective and improve outcomes, researchers report in the March issue of Clinical Gastroenterology and Hepatology. There has been a steady increase in the number of

Read more

How Can We Tell if Patients are Still at Risk for HCC after HCV Therapy?

For patients with chronic Hepatitis C virus infection, high levels of α-fetoprotein after therapy can identify those at risk for hepatocellular carcinoma (HCC), researchers report in the July issue of Clinical Gastroenterology and Hepatology. In persons with chronic HCV infection, lack of sustained virologic response (SVR) 24 weeks after the end

Read more